Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,883 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC.
Brockwell NK, Owen KL, Zanker D, Spurling A, Rautela J, Duivenvoorden HM, Baschuk N, Caramia F, Loi S, Darcy PK, Lim E, Parker BS. Brockwell NK, et al. Among authors: lim e. Cancer Immunol Res. 2017 Oct;5(10):871-884. doi: 10.1158/2326-6066.CIR-17-0150. Epub 2017 Aug 28. Cancer Immunol Res. 2017. PMID: 28848054
Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer.
Cazet AS, Hui MN, Elsworth BL, Wu SZ, Roden D, Chan CL, Skhinas JN, Collot R, Yang J, Harvey K, Johan MZ, Cooper C, Nair R, Herrmann D, McFarland A, Deng N, Ruiz-Borrego M, Rojo F, Trigo JM, Bezares S, Caballero R, Lim E, Timpson P, O'Toole S, Watkins DN, Cox TR, Samuel MS, Martín M, Swarbrick A. Cazet AS, et al. Among authors: lim e. Nat Commun. 2018 Jul 24;9(1):2897. doi: 10.1038/s41467-018-05220-6. Nat Commun. 2018. PMID: 30042390 Free PMC article. Clinical Trial.
Non-canonical AR activity facilitates endocrine resistance in breast cancer.
Chia K, Milioli H, Portman N, Laven-Law G, Coulson R, Yong A, Segara D, Parker A, Caldon CE, Deng N, Swarbrick A, Tilley WD, Hickey TE, Lim E. Chia K, et al. Among authors: lim e. Endocr Relat Cancer. 2019 Feb 1;26(2):251-264. doi: 10.1530/ERC-18-0333. Endocr Relat Cancer. 2019. PMID: 30557851
Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.
Kennedy SP, Han JZR, Portman N, Nobis M, Hastings JF, Murphy KJ, Latham SL, Cadell AL, Miladinovic D, Marriott GR, O'Donnell YEI, Shearer RF, Williams JT, Munoz AG, Cox TR, Watkins DN, Saunders DN, Timpson P, Lim E, Kolch W, Croucher DR. Kennedy SP, et al. Among authors: lim e. Breast Cancer Res. 2019 Mar 21;21(1):43. doi: 10.1186/s13058-019-1127-y. Breast Cancer Res. 2019. PMID: 30898150 Free PMC article.
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Portman N, Milioli HH, Alexandrou S, Coulson R, Yong A, Fernandez KJ, Chia KM, Halilovic E, Segara D, Parker A, Haupt S, Haupt Y, Tilley WD, Swarbrick A, Caldon CE, Lim E. Portman N, et al. Among authors: lim e. Breast Cancer Res. 2020 Aug 12;22(1):87. doi: 10.1186/s13058-020-01318-2. Breast Cancer Res. 2020. PMID: 32787886 Free PMC article.
Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.
Chew NJ, Lim Kam Sian TCC, Nguyen EV, Shin SY, Yang J, Hui MN, Deng N, McLean CA, Welm AL, Lim E, Gregory P, Nottle T, Lang T, Vereker M, Richardson G, Kerr G, Micati D, Jardé T, Abud HE, Lee RS, Swarbrick A, Daly RJ. Chew NJ, et al. Among authors: lim e, lim kam sian tcc. Breast Cancer Res. 2021 Aug 3;23(1):82. doi: 10.1186/s13058-021-01461-4. Breast Cancer Res. 2021. PMID: 34344433 Free PMC article.
A new sophistication for breast cancer PDXs.
Portman N, Lim E. Portman N, et al. Among authors: lim e. Nat Cancer. 2022 Feb;3(2):138-140. doi: 10.1038/s43018-021-00328-z. Nat Cancer. 2022. PMID: 35221337 No abstract available.
An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer.
Lim E, Boyle F, Okera M, Loi S, Goksu SS, van Hal G, Chapman SC, Gable JC, Chen Y, Price GL, Hossain AM, Gainford MC, Ezquerra MB. Lim E, et al. Breast Cancer Res Treat. 2022 Oct;195(3):275-287. doi: 10.1007/s10549-022-06690-5. Epub 2022 Aug 1. Breast Cancer Res Treat. 2022. PMID: 35915198 Free PMC article. Clinical Trial.
2,883 results